The HIV Vaccine Awareness Day 2017 webinar series kicked off with an overview of the Ad26/mosaic vaccine efficacy program from Janssen’s Maria Grazia Pau. This strategy is notable both for the science and for the active leadership from industry. Dr. Pau did a terrific job of explaining where the strategy fits into the broader vaccine field.

Recording Available: YouTube / Audio / Slides

This was one in a series of HIV Vaccine Awareness Day webinars. For details on all other calls, including recordings, visit here.

Long-time vaccine researcher Barney Graham presented an excellent overview of the history and work of NIH’s Vaccine Research Center (VRC)—established two decades ago on the inaugural HIV Vaccine Awareness Day (HVAD) in 1997. Download the recording for an accessible overview of the HIV vaccine field, the connections between the work on HIV and other vaccines at the VRC and tips on what advocates and researchers should be calling for this HVAD.

Recording Available: YouTube / Audio / Slides

This was one in a series of HIV Vaccine Awareness Day webinars. For details on all other calls, including recordings, visit here.

Dr. Fatima Laher, protocol co-chair of HVTN 702, provides an overview of the first HIV vaccine efficacy trial in seven years. Her presentation looks at the history, starting with partial success of RV144 in 2009, and talks about the role HVTN 702 as the field advances toward an effective vaccine.

Recording: YouTube / Audio / Slides

This was one in a series of HIV Vaccine Awareness Day webinars. For details on all other calls, including recordings, visit here.

Dr. Lynn Morris, head of HIV Virology at South Africa’s National Institute for Communicable Diseases and professor at the University of the Witwatersrand in Johannesburg, provided an overview of antibody research for HIV prevention. She laid out the current landscape; provided a glimpse of what is to come in this dynamic field; talked about where antibody work fits in the larger field of prevention research; and described how the Antibody Mediated Prevention (AMP) studies – ongoing proof-of-concept trials of the broadly neutralizing antibody VRC01 – might advance HIV prevention.

This was the fourth in our series of HIV Vaccine Awareness Day webinars. For details on the full series, visit avac.org/hvad.

Recording: YouTube / Audio / Slides

For more information, including the At-A-Glance and full program, click here.

Where:
Omni Shoreham Hotel
2500 Calvert Street NW
Washington, DC 20008

Lieutenant Colonel Julie Ake, Principal Deputy Director of the US Military HIV Research Program (MHRP), wraps up our HVAD webinar series by providing an overview of MHRP’s HIV program and helping to connect dots in the HIV vaccine field.

Ake takes us through the landmark RV144 trial, the first HIV vaccine trial to show efficacy, and gives a clear and compelling update on where HIV vaccine research is and where it needs to go to ensure the development of a safe and effective vaccine. She also provides insight into the linkages to HIV treatment and cure research, as well as other vaccine development efforts, illuminating in particular the ways in which HIV vaccine research has informed Ebola and Zika vaccine development.

This was the fifth in our series of HIV Vaccine Awareness Day webinars. For details on the full series, visit avac.org/hvad.

Recording: YouTube / Audio / Slides

Professor Linda-Gail Bekker is the Deputy Director of the Desmond Tutu HIV Centre, Chief Operating Officer at the Desmond Tutu HIV Foundation and Professor of Medicine at the University of Cape Town. She is also President-elect of the International AIDS Society.

Amongst many HIV prevention research activities that she leads, she is the principal investigator of the HVTN 100 vaccine trial, and in this webinar she discussed the latest in HIV vaccine research and the most recent updates on the plan to start a new vaccine efficacy trial later this year.

Listen / View Slides / Watch on YouTube / Watch Flash animation

John Mascola of the NIH Vaccine Research Center spoke about harnessing antibodies for HIV prevention and treatment. The recording includes a question and answer period with webinar participants.

For further background, click here to view his CROI plenary session. And this webinar is part of our post-CROI 2016 webinar series. Click to learn more.

Where: The New York Academy of Sciences Conference Center in Manhattan

Presented by: UNAIDS and the Microbiology & Infectious Diseases Discussion Group at the New York Academy of Sciences

Speakers:

• Steven G. Deeks, MD, University of California, San Francisc
• Peter Godfrey-Faussett, BA, MBBS, DTM&H, FRCP (UK), UNAID
• Maureen M. Goodenow, PhD, University of Florida Healt
• James Hakim, MBChB, FRCP, University of Zimbabw
• Mark Harrington, Treatment Action Grou
• Peter Lamptey, MD, DrPH, MPH, FHI36
• Linda Kupfer, PhD, Fogarty International Center, NI
• Luiz Loures, MD, MPH, UNAID
• Wafaa El Sadr, MD, MPH, Mailman School of Public Health, Columbia Universit
• Doug Webb, PhD, HIV, Health and Development Group, UNDP